



VNS in pain 
 
 
The first investigations on the modulation of nociception by vagal afferents were 
performed approximately 20 years ago. Contrasted results emerged from experiments in 
animal with pro-nociceptive or anti-nociceptive actions of VNS depending on the 
stimulus parameters and the species examined. It appears that low intensity stimulations 
of cervical vagal afferents facilitate, but high intensity stimulations inhibit nociception. 
The analgesic effects of VNS seems to depend on a critical stimulation intensity that 
activates C fibres. 
Recently, cervical vagal nerve stimulators have been implanted in humans for 
epilepsy treatment and pain studies have been conducted in such patients. Those clinical 
data confirmed the complexity of VNS effects with contradictory results reported on pain 
thresholds. Indeed, in one study, VNS induced a significant decrease of thermal 
thresholds when low intensity stimulations were used during the “ON” cycle (acute 
effects). In an other study, VNS induced on the contrary, an increase in mechanical pain 
thresholds independently of the ON-OFF cycles (chronic effects) but no changes of heat 
pain thresholds. However, beside clinical experimental studies, recent reports have 
described  reductions in headache frequency and headache intensity 1 to 3 months after 
VNS treatment initiation in epileptic migraine sufferer patients and a pilot study showed 
a beneficial effect of VNS in chronic daily headache patients. Furthermore, thalamic 
activation demonstrated with positron emission tomography during VNS in epileptic 
patients as well as hypothalamic activation associated with increased release of ACTH 
and corticosterone could be some of the supraspinal mediators of antinociceptive and 
anti-inflammatory effects of VNS. 
Prior to specifically applying VNS in the treatment of refractory pain in humans, the 
most efficient stimulation protocol need to be defined and underlying neuronal pain 
control processes in those conditions better understood. We have therefore used a 
commercially available device (NCP-Cyberonics) to examine the effect of left cervical 
VNS on several kinds of pain model in rat involving acute or inflammatory pain. We 
demonstrate clear antinociceptive effects under different VNS conditions including with 
parameters tolerable by patients, i.e. those already used in epilepsy therapy. We also 
show that several structures could be involved in those VNS analgesics effects among 
them the caudal trigeminal nucleus. 
All together, those data suggest that VNS may be effective in the treatment of pain 
and potentially useful in resistant head and facial pain syndrome. 
